Intramyocardial Injection of Autologous UCB-MNC During Fontan Surgery for SRV Dependent CHD

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 1, 2021

Primary Completion Date

May 24, 2023

Study Completion Date

August 30, 2025

Conditions
Congenital Heart Disease, SRV Dependent
Interventions
BIOLOGICAL

Autologous mononuclear cells

Autologous mononuclear cells delivered into right ventricle at time of Stage III Fontan surgery.

Trial Locations (6)

19104

Children's Hospital of Philadelphia, Philadelphia

35233

University of Alabama Medical Center, Birmingham

55905

Mayo Clinic, Rochester

73104

University of Oklahoma Medical Center, Oklahoma City

80045

Children's Hospital Colorado, Aurora

90027

Children's Hospital Los Angeles, Los Angeles

Sponsors
All Listed Sponsors
collaborator

Mayo Clinic

OTHER

collaborator

University of Oklahoma

OTHER

collaborator

Children's Hospital of Philadelphia

OTHER

collaborator

Children's Hospital Los Angeles

OTHER

collaborator

Children's Hospitals and Clinics of Minnesota

OTHER

collaborator

Children's Hospital Colorado

OTHER

collaborator

Ochsner Health System

OTHER

collaborator

Children's of Alabama

OTHER

collaborator

Children's Hospital Medical Center, Cincinnati

OTHER

collaborator

The Hospital for Sick Children

OTHER

lead

Timothy J Nelson, MD, PhD

OTHER